P3 Health Partners Sees Bright Future as it Embarks on Significant Smart Growth
P3 Health Partners, a leading healthcare provider, recently reported its Q4 2025 earnings, showcasing a promising trajectory for the company in the coming year. CEO Aric Coffman led the conference call, highlighting the significant smart growth the company is experiencing and its expectations for 2026.
According to Coffman, P3 Health Partners has identified $170 million of structural and operational improvement opportunities that will drive a substantial reduction in costs and improve revenue. These efforts focus on contracting and revenue-related actions ($125 million), operational execution around MedEx initiatives and network contracting ($35 million), and payer benefit design, collaboration, and membership profile ($10 million).
The company's financial guidance for 2026 reflects these improvements, with a midpoint Adjusted EBITDA of $10 million, representing a significant improvement from the 2025 Adjusted EBITDA loss of $161 million. Coffman emphasized that this growth is supported by actions already underway and provides a clear path to achieving their 2026 outlook.
P3 Health Partners focused on strengthening its foundation in 2025, improving contracts, increasing provider alignment and accountability, and advancing clinical and quality performance. The company secured meaningful improvements across key payer relationships and refined its network to concentrate on providers aligned with value-based care.
Notably, P3 Health Partners made progress on quality, achieving Four-Star status across 70% of their priority Medicare Advantage plans. This reinforces the company's value proposition with payer partners and supports future growth. As a result, Coffman expressed high confidence in the company's guidance for 2026.
The company's commitment to smart growth and its focus on improving operational efficiency are likely to yield positive results in the coming year. With clear visibility into their performance improvement plan and significant cost reductions already underway, P3 Health Partners appears poised for a strong future.
